Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

New Software Simplifies Performing and Analyzing Dissolution via HPLC

By BiotechDaily International staff writers
Posted on 22 May 2013
Image: The Agilent LC Dissolution Software module (Photo courtesy of Agilent Technologies).
Image: The Agilent LC Dissolution Software module (Photo courtesy of Agilent Technologies).
A new software module simplifies the quantification and reporting of dissolution samples analyzed by HPLC, maximizing the user's investment in dissolution apparatus, liquid chromatographs, and informatics.

Agilent Technologies Inc. (Santa Clara, CA, USA) now offers the new “LC Dissolution Software,” an add-on module for use with the ChemStation Edition of the Agilent OpenLAB Chromatography Data System. Once dissolution samples have been collected, they are loaded into the chromatograph and analyzed. The LC Dissolution Software module automates the setup of the chromatograph, incorporates the dissolution methodology, performs the sample analysis, and generates the final reports. Real-time views of the dissolution profile of all active ingredients are available as the analysis progresses.

"Customers can maximize their current workflow by integrating dissolution with LC analysis using LC Dissolution Software," said Allan Little, Agilent director of marketing for dissolution systems; "This software eliminates the need to export data to a spreadsheet and thus ensures the integrity and security of dissolution analysis data, all in a 21 CFR Part 11 environment."

Additional key product features include existing chromatographic methods that easily integrate for automatic generation of analysis sequences, sequence generation independent of hardware, and full utilization of all Agilent LC ChemStation software capabilities.

Related Links:

Agilent Technologies
LC Dissolution Software



WATERS CORPORATION

Channels

Business

view channel

License Agreement to Promote Development of Therapeutic CDK Inhibitors

A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections. Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.